Half-year report
February – July 2012

PHOENIX group

- Stable business developments enabled the PHOENIX group to consolidate its position in Europe as leading pharmaceuticals distributor in the first quarter
- Sales development influenced by the low growth of pharmaceutical markets and lower sales volume in Germany
- Improvement of gross profit margin from 9.03 % to 9.71 %
- New retail brand BENU successfully started
- Successful early refinancing in conjunction with the syndicated loan in the second quarter
- Profit for the period adjusted for transaction costs due to the refinancing ("adjusted profit for the period") above prior year's level

EUR k	1st half year 2011	1st half year 2012
Revenue	10,877,565	10,518,844
Gross profit	982,681	1,021,899
Earnings before interest, taxes, depreciation and amortisation (EBITDA)	284,293	276,433
Adjusted EBITDA	298,419	288,233
Earnings before interest and taxes (EBIT)	237,420	225,971
Financial result	-72,934	-78,717
Profit before tax	164,486	147,254
Profit for the period	114,680	103,962
Adjusted profit for the period	114,680	119,436

EUR k	31 Jan 2012	31 Jul 2012
Equity	1,935,623	2,006,753
Equity ratio	26.1 %	27.5 %
Net debt	1,855,743	2,010,074

PHOENIX Pharmahandel GmbH & Co KG, Mannheim

Half-year report February – July 2012

Interim group management report

Interim condensed consolidated financial statements

PHOENIX Pharmahandel GmbH & Co KG
Interim group management report

Business and economic environment

Development of the market

In the first half year the economic development in Europe was still weak compared to the prior year. Germany's real GDP grew by 1.2 % in the first quarter and by 1.0 % in the second quarter compared to last year's quarters. However, in the euro zone there was a decrease of 0.2 % compared to the second quarter of 2011. The economic environment was characterized by the ongoing debt crisis of public finances in various European countries.

In this difficult economic environment, growth in the pharmaceutical markets was still weak. The wholesale pharmaceuticals market in Germany for the period January to July 2012 compared to the same period last year grew by 1.45 %.

Other countries in Western Europe saw diverse market developments. In the UK the pharmaceutical market was stable compared to prior year. In the Netherlands, due to price reductions, the market declined. Since the beginning of this year, a new remuneration policy for pharmacies came into effect under which the remuneration of pharmacies can be agreed in contracts with the various health insurance funds without restriction. The French market was still shaped by intense competition after the introduction of a new margin system in the beginning of the year 2012. Switzerland and Austria showed a remarkable market growth. The Italian market declined in a difficult economic environment due to price reductions for prescription pharmaceuticals.

In Eastern Europe the pharmaceutical markets in the Czech Republic and Bulgaria showed a slight increase compared with last year's first half year. In Hungary, state healthcare policy measures in the first half year resulted in a significant market decline.

In Northern Europe the pharmacy markets in Finland and Norway increased whereas the Danish and the Swedish market showed a decrease.

New retail brand BENU

In the first half year, PHOENIX has successfully introduced the retail brand BENU. In total, more than 700 pharmacies in selected countries will be united under this brand. The new store concept, comprising shopfittings, optimisation of the presentation of goods as well as an individual consultation of customers has already been successfully implemented in several countries.

Acquisitions, investments and joint ventures

As in the prior year, we pursued a cautious acquisition strategy in the first half year of the fiscal year 2012/13. In total, business combinations in the first half year led to a cash outflow of EUR 3.9m (comparative period: EUR 7.6m).

The business combinations were immaterial and primarily concerned individual pharmacies in various countries.

Results of operations, net assets and financial position

Results of operations

Revenue decreased in the first half year of 2012/13 to EUR 10,518.8m (comparative period: EUR 10,877.6). The main reasons for this development were the overall comparatively weak growth in the European pharmaceutical markets and a decline in sales in our biggest market, Germany, where we were aiming at a sales policy to stabilize margins in a challenging market environment and consequently had to suffer some temporary losses in sales. This could partly be compensated by increased revenue in several foreign markets. The gross profit margin has improved from 9.03 % to 9.71 %. In absolute terms the gross profit has increased by EUR 39.2m to EUR 1,021.9m.

Other operating income declined by EUR 1.2m to EUR 74.2 m.

Personnel expenses rose by EUR 32.6m to EUR 534.0m. The increase in personnel expenses is mainly a result of increases in pay rates, exchange rate effects and changes in the consolidated group.

Other expenses increased by EUR 13.3m to EUR 287.3m. This is mainly due to increased transportation costs, an increase in consultancy costs as well as maintenance and marketing expenses.

Earnings before interest, tax, depreciation and amortisation (EBITDA) changed by EUR 7.9m to EUR 276.4m. The increase in gross profit was not sufficient to cover the overall increase in expenses.

The EBITDA indicator used for comparison with our net debt (adjusted EBITDA) of EUR 288.2m was 3.4 % below the comparative period level and is determined as follows:

EUR k	1st half-year 2011	1st half-year 2012
EBITDA	284,293	276,433
Interest from customers	12,018	9,649
Factoring fees	2,108	2,151
Adjusted EBITDA	**298,419**	**288,233**

Depreciation increased by EUR 3.6m to EUR 50.5m compared to last year's half year. This is mainly caused by increased investments in fixed assets.

Earnings before interest and tax (EBIT) changed due to the development of EBITDA and depreciation from EUR 237.4m in the comparative period to EUR 226.0m. The EBIT margin in relation to revenue is stated at 2.15 % (comparative period: 2.18 %).

The financial result compared to prior period's result changed by EUR -5.8m to EUR -78.7m. Interest income declined by EUR 17.5m to EUR 15.1m. Interest expense increased from EUR 89.8m to EUR 93.9m. The main reason for this increase is the premature amortisation of transaction costs with an amount of EUR -18.4m in conjunction with the refinancing in June 2012. Adjusted for this effect, the financial result increased by EUR 12.6m compared to prior year's half year.

Profit before tax changed by EUR 17.2m to EUR 147.3m due to the change in EBITDA as well as the change in the financial result.

The effective tax rate declined from 30.3 % to 29.4 %. This is mainly a result from a reduction in income tax rates in the UK.

Profit after tax amounts to EUR 104.0m (comparative period: EUR 114.7m). Of this, EUR 5.1m is attributable to non-controlling interests (comparative period: EUR 8.8m).

Adjusted for the premature amortisation of transaction costs, profit after tax amounts to EUR 119.4m and was slightly above prior year's result of EUR 114.7m

Net assets

The Group's total assets decreased by 1.4 % to EUR 7,307.8m. The currency translation difference on the total assets, which is presented in the statement of changes in equity, amounts to EUR -63.5m (31 January 2012: EUR -84.9m).

Compared to 31 January 2012, non-current assets rose by EUR 89.6m to EUR 2,686.6m. The increase is mainly caused by exchange rate effects, especially due to changes in the currency rates of the British Pound and the Norwegian and Swedish Crown, increased fixed assets under construction as well as higher deferred tax assets. Intangible assets contain goodwill with an amount of EUR 1,265.1m (31 January 2012: EUR 1,251.3m).

Inventories increased compared to 31 January 2012 by EUR 115.9m to EUR 1,810.4m. This increase is mainly due to seasonal fluctuation.

Trade receivables decreased by 5.2% to EUR 2,402.8m. Receivables of EUR 380.4m (31 January 2012: EUR 340.1m) had been sold under ABS and factoring programmes that are either not accounted for in the statement of financial position or are accounted for only to the extent of the continuing involvement.

Other current receivables and financial assets increased from EUR 148.9m as of 31 January 2012 to EUR 172.1m. The increase is mainly due to higher receivables in conjunction with ABS and factoring programmes and higher rebates and discounts.

Other current assets increased from EUR 80.9m as of 31 January 2012 to EUR 106.0m among others due to higher prepayments.

The change in cash and cash equivalents is presented in the statement of cash flows.

.

Financial position

Equity increased mainly due to the profit for the period as well as changes in the translation differences. This is counterbalanced by the actuarial losses relating to pension obligations.

Cash flow from operating activities came to EUR -24.6m (comparative period: EUR +69.2m). In comparison to last year there was a higher increase in working capital by EUR 120.8m which resulted in a decline in cash flow from operating activities.

Cash flow from investing activities amounted to EUR -70.0m. In the comparative period, the cash flow from investing activities amounted to EUR -40.4m. The increase is mainly due to higher investments in fixed assets and less cash received from the disposal of fixed assets.

At 27 June 2012, the new financing of the PHOENIX group has come into force. The new credit facility consists of a term loan, presented under non-current financial liabilities, with a nominal amount of EUR 300.0m and a term of four years as well as a revolving credit facility of EUR 1,050.0m with a term of five years which will be drawn on a short-term basis as and when required. Accordingly, long-term bank liabilities decreased from EUR 651.8m as of 31 January 2012 to EUR 298.7m as of 31 July 2012. Short-term bank liabilities increased compared to 31 January 2012 by EUR 312.0m to EUR 572.9m.

Besides liabilities to banks, non-current financial liabilities include bonds of EUR 485.1m (31 January 2012: EUR 482.4m), supplementary partner contributions with an amount of EUR 123.8m (31 January 2012: EUR 123.8m) as well as finance lease liabilities with an amount of EUR 23.5m (31 January 2012: EUR 23.7m).

Besides liabilities to banks, current financial liabilities include among others liabilities from ABS and factoring agreements with an amount of EUR 223.1 Mio EUR (31 January 2012: EUR 266.2m) as well as other loans amounting to EUR 108.9m (31 January 2012: EUR 110.5m).

Trade payables decreased by EUR 118.3m to EUR 2,462.3m.

Other liabilities fell from EUR 278.1m as of 31 January 2012 to EUR 258.1m. The decrease is primarily due to lower other taxes.

The objective of financial management is to continuously improve the capital structure by reducing the gearing ratio. In the medium term, we aim to further strengthen the equity ratio by retaining profits and to achieve a ratio of net debt to EBITDA of below 3.0.

Overall the PHOENIX group was able to underline its position in the first half year of the fiscal year 2012/13 as leading pharmaceuticals distributor in Europe and to report a stable business performance.

Risks and opportunities

The PHOENIX group has comprehensive planning, approval and reporting structures and an early warning system which we use to identify, assess and monitor our opportunities and risks. The opportunities and risks of significance to us are presented extensively in our annual report for fiscal 2011/12.

The risks presented there are still essentially relevant.

Forecast

On the whole, we still do not expect the pharmaceutical markets in Europe to record growth in the fiscal year 2012/13. Cost-cutting measures introduced by healthcare policymakers and uncertainty about the situation of the economy as a whole in relation to the European debt crisis are likely to curb growth on the pharmaceutical markets.

In the first half year, revenue was 3.3% below prior year's amount. We expect that the decline in revenue will reduce in the second half year. For the whole fiscal year, we expect revenue to be slightly below prior year's level.

However, at the level of adjusted EBITDA, we still expect to reach the 2011/12 level in the fiscal year 2012/13.

PHOENIX Pharmahandel GmbH & Co KG, Mannheim

Half-year report February – July 2012

Interim condensed consolidated financial statements

Consolidated income statement for the first half year of 2012/13

EUR k	2nd quarter 2011*	2nd quarter 2012	1st half-year 2011*	1st half-year 2012
Revenue	**5,480,272**	**5,321,399**	**10,877,565**	**10,518,844**
Cost of purchased goods and services	-4,982,796	-4,801,149	-9,894,884	-9,496,945
Gross profit	**497,476**	**520,250**	**982,681**	**1,021,899**
Other operating income	38,550	35,566	75,335	74,172
Personnel expenses	-250,690	-267,474	-501,439	-534,014
Other operating expenses	-138,562	-143,353	-273,999	-287,297
Results from associates	1,076	1,023	1,300	1,400
Result from other investments	167	170	415	273
Earnings before interest, taxes depreciation and amortisation (EBITDA)	**148,017**	**146,182**	**284,293**	**276,433**
Amortisation of intangible assets and depreciation of property, plant and equipment	-23,494	-25,744	-46,873	-50,462
Earnings before interest and taxes (EBIT)	**124,523**	**120,438**	**237,420**	**225,971**
Interest and similar income	9,402	8,597	17,452	15,090
Interest and similar expenses	-44,231	-36,976	-89,773	-93,868
Other financial result	-2,387	258	-613	61
Financial result	**-37,216**	**-28,121**	**-72,934**	**-78,717**
Profit before tax	**87,307**	**92,317**	**164,486**	**147,254**
Income taxes	-26,282	-27,388	-49,806	-43,292
Profit for the period	**61,025**	**64,929**	**114,680**	**103,962**
thereof attributable to non-controlling interests	4,846	2,598	8,787	5,126
thereof attributable to owners of the parent company	**56,179**	**62,331**	**105,893**	**98,836**

* Prior-year figures were restated due to changes in the presentation within financial result.

Consolidated statement of comprehensive income for the first half year of 2012/13

EUR k	2nd quarter 2011	2nd quarter 2012	1st half-year 2011	1st half-year 2012
Profit for the period	**61,025**	**64,929**	**114,680**	**103,962**
Actuarial gains and losses from pension obligations	-56,572	-52,262	-68,716	-68,281
Gains/losses from changes in the fair value of available-for-sale financial assets	-1,484	-82	-1,718	-239
Currency translation differences	722	11,099	-7,079	21,023
Deferred taxes on other comprehensive income	15,122	13,822	18,368	17,952
Other comprehensive income, net of taxes	**-42,212**	**-27,423**	**-59,145**	**-29,545**
Total comprehensive income	**18,813**	**37,506**	**55,535**	**74,417**
thereof attributable to non-controlling interests	-1,897	1,163	2,808	2,707
thereof attributable to owners of the parent company	**20,710**	**36,343**	**52,727**	**71,710**

Consolidated statement of financial position as of 31 July 2012

EUR k	31 Jan 2012	31 Jul 2012
Non-current assets		
Intangible assets	1,601,119	1,635,160
Property, plant and equipment	779,102	804,096
Investment property	5,326	5,224
Investments in associates	18,842	20,059
Other financial assets	64,250	62,419
Deferred tax assets	124,265	155,562
Income tax receivables	4,052	4,052
	2,596,956	**2,686,572**
Current assets		
Inventories	1,694,509	1,810,364
Trade receivables	2,533,903	2,402,754
Income tax receivables	12,643	12,052
Other receivables and other current financial assets	148,894	172,065
Other assets	80,850	106,040
Cash and cash equivalents	334,846	109,772
	4,805,645	**4,613,047**
Non-current assets classified as held for sale	8,415	8,166
Total assets	**7,411,016**	**7,307,785**

Consolidated statement of financial position as of 31 July 2012

EUR k	31 Jan 2012	31 Jul 2012
Equity		
Unlimited and limited partners' capital	1,050,000	1,050,000
Reserves	885,914	984,209
Other comprehensive income	-200,091	-227,217
Equity attributable to partners	**1,735,823**	**1,806,992**
Non-controlling interests	199,800	199,761
	1,935,623	**2,006,753**
Non-current liabilities		
Financial liabilities	1,285,153	935,342
Provisions for pensions and similar obligations	282,864	361,413
Deferred tax liabilities	133,633	140,354
Other non-current liabilities	6,962	7,104
	1,708,612	**1,444,213**
Current liabilities		
Financial liabilities	751,223	1,012,593
Trade payables	2,580,564	2,462,300
Other provisions	58,028	25,127
Income tax liabilities	98,773	98,653
Other liabilities	278,114	258,106
	3,766,702	**3,856,779**
Liabilities directly associated with assets classified asheld for sale	79	40
Total equity and liabilities	**7,411,016**	**7,307,785**

Statement of changes in equity for the first quarter of 2012/13

EUR k	Unlimited and limited partners' capital	Reserves
1 February 2011	**1,050,000**	**674,840**
Profit for the period		105,893
Other comprehensive income		0
Total comprehensive income, net of tax	**0**	**105,893**
Changes in consolidated group		-714
Dividends		0
31 Jul 2011	**1,050,000**	**780,019**
1 February 2012	**1,050,000**	**885,914**
Profit for the period		98,836
Other comprehensive income		0
Total comprehensive income, net of tax	**0**	**98,836**
Capital increase/reduction		0
Changes in consolidated group		-541
Dividends		0
31 Jul 2012	**1,050,000**	**984,209**

Currency translation difference	IAS 39 Available-for-sale financial assets	Actuarial gains/losses	Equity attributable to partners	Non-controlling interests	Total equity
-83,930	**12,304**	**-65,806**	**1,587,408**	**185,001**	**1,772,409**
			105,893	8,787	114,680
-7,269	-1,678	-44,219	-53,166	-5,979	-59,145
-7,269	**-1,678**	**-44,219**	**52,727**	**2,808**	**55,535**
			-714	430	-284
			0	-1,952	-1,952
-91,199	**10,626**	**-110,025**	**1,639,421**	**186,287**	**1,825,708**
-84,874	**9,879**	**-125,096**	**1,735,823**	**199,800**	**1,935,623**
			98,836	5,126	103,962
21,410	-175	-48,361	-27,126	-2,419	-29,545
21,410	**-175**	**-48,361**	**71,710**	**2,707**	**74,417**
			0	1,402	1,402
			-541	-1,020	-1,561
			0	-3,128	-3,128
-63,464	**9,704**	**-173,457**	**1,806,992**	**199,761**	**2,006,753**

Consolidated statement of cash flows for the first half year of 2012/13

EUR k		1st half year 2011	1st half year 2012
Profit for the period		**114,680**	**103,962**
+/-	Write-downs/write-ups of fixed assets	46,873	50,462
-/+	Gain/loss from the disposal of fixed assets	-4,362	850
+/-	Increase/decrease in non-current provisions	1,446	1,959
+/-	Other non-cash expenses/income	12,987	15,879
+	Net interest	70,179	79,478
+	Taxation	49,806	43,292
-	Interest paid	-88,818	-66,028
+	Interest received	16,499	13,793
-	Income tax paid	-50,450	-49,756
+	Dividends received	219	336
Result before changes in working capital		**169,059**	**194,227**
Changes in working capital		**-99,895**	**-220,665**
Cash inflow (+)/outflow (-) from operating activities		**69,164**	**-26,438**
-	Cash paid for the purchase of consolidated companies and business units	-7,614	-3,942
+	Cash received from the purchase of consolidated companies and business units	3,516	42
+	Cash received from disposals of fixed assets	15,975	4,494
-	Cash paid for investments in fixed assets	-52,241	-70,577
Cash inflow (+)/outflow (-) from investing activities		**-40,364**	**-69,983**

Consolidated statement of cash flows for the first half year of 2012/2013

EUR k		1st half year 2011	1st half year 2012
Cash available for financing activities		**28,800**	**-96,421**
+/-	Capital increase/decrease	0	1,278
-	Payments to minority interests (dividends)	-1,582	-1,675
-	Purchase of additional interests in subsidiaries	0	-2,750
+/-	Increase/decrease in ABS/factoring liabilities	4,184	-45,983
+	Cash received from the issue of bonds and loans	71,325	675,342
-	Cash repayments of bonds and loans	-464,375	-754,566
+/-	Increase/decrease in finance lease liabilities	-1,478	-596
Cash inflow (+)/outflow (-) from financing activities		**-391,926**	**-128,950**
Change in cash and cash equivalents		**-363,126**	**-225,371**
Cash and cash equivalents at the beginning of the period		**578,713**	**334,846**
Exchange rate effect on cash and cash equivalents		180	297
Cash and cash equivalents at the end of the period		**215,767**	**109,772**

PHOENIX Pharmahandel GmbH & Co KG, Mannheim
Notes to the interim condensed consolidated financial statements as of 31 July 2012

The company

PHOENIX Pharmahandel GmbH & Co KG, Mannheim, ("PHOENIX" or the "Group") is a European pharmaceuticals distribution group. PHOENIX has business activities in 23 European countries. In several countries, PHOENIX also operates own pharmacy chains. The registered office is located in Mannheim, Germany.

Basis of presentation

The interim condensed consolidated financial statements of PHOENIX as of 31 July 2012 are prepared on the basis of IAS 34 "Interim Financial Reporting", observing all International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), London, and mandatory in the EU as of 31 July 2012, as well as all mandatory interpretations of the International Financial Reporting Standards Interpretation Committee (IFRIC).

The interim condensed consolidated financial statements as of 31 July 2012 of PHOENIX were released for publication by the management of PHOENIX Pharmahandel GmbH & Co KG on 13 September 2012.

Significant accounting policies

The accounting policies used to prepare the interim condensed consolidated financial statements are essentially consistent with those used in the consolidated financial statements as of 31 January 2012. Any differences are explained below. The standard *IFRS 7: Disclosures: transfer of financial asset*s whose application was mandatory for the first time from 1 February 2012 did not have any impact on the interim financial statements.

Business combinations in the first half year of 2012/13

The business combinations carried out in the first half of 2012/13 are explained below. Purchase accounting is performed in accordance with the acquisition method pursuant to IFRS 3 "Business Combinations".

In fiscal 2012/13, the cumulative profit for the period of the acquirees came to EUR 244k. Assuming that the acquisition date coincides with the beginning of the reporting period for all business combinations, accumulated revenue for the period came to EUR 7,044k. Assuming that the acquisition date coincides with the beginning of the reporting period for all business combinations, the accumulated profit for the period came to EUR 412k.

The business combinations performed in the first half of 2012/13 were individually immaterial and related to certain pharmacies in various countries

The table below shows a summary of their fair values:

Fair value recognised on acquisition

EUR k	Others
Cash and cash equivalents	3,255
Equity instruments	0
Acquisition-date fair value of previously held equity interests	0
Consideration transferred	**3,255**
Other non-current assets	45
Inventories	584
Trade receivables	589
Cash and cash equivalents	755
Other current assets	54
Current liabilities	1,270
Net assets	**757**
Non-controlling interests	-20
Net assets required	**777**
Bargain purchase	**0**
Goodwill	**2,478**

Other business combinations

In the first half of 2012/13, the Group acquired further pharmacies in business combinations that are individually immaterial.

The goodwill arising on those acquisitions was allocated to the cash-generating units Switzerland (EUR 1,354k), Norway (EUR 622k) and Estonia (EUR 502k) and is managed in the local functional currencies (CHF, NOK and EUR).

Non-controlling interests are recognised at the share of the identifiable net assets in the acquirees.

EUR 1,354k of the goodwill recognised from business combinations is expected to be tax deductible.

Because of preliminary data, some assets and liabilities couldn't be finally valued at the balance sheet date.

Other operating expenses

Other operating expenses contain expenses in connection with ABS and factoring programmes of EUR 2,151k (comparative period: EUR 2,108k).

Financial result

EUR k	1st half year 2011*	1st half year 2012
Interest and similar income		
Interest income	16,879	14,138
Other financial income	573	952
	17,452	**15,090**
Interest and similar expenses		
Interest expenses	-87,058	-93,616
Other financial expenses	-2,715	-252
	-89,773	**-93,868**
Other financial result	**-613**	**61**
Financial result	**-72,934**	**-78,717**

* Prior-year figures have been restated due to changes in presentation.

Interest income includes interest from customers of EUR 9,649k (comparative period: EUR 12,018k).

Interest expenses include EUR 18,433k (comparative period: EUR 0) in connection with the premature amortisation of transaction costs in conjunction with the refinancing.

In order to improve the presentation of the components of financial result, currency effects and changes in the fair value of derivative financial instruments that were used to hedge interest rate and currency risks but do not meet the criteria for hedge accounting are disclosed in the other financial result. The comparative figures were restated accordingly. The other financial result includes exchange rate gains of EUR 49,830k (comparative period: EUR 72,274k) and exchange rate losses of EUR 36,276k (comparative period: EUR 60,293k). Changes in the market value of deriva-tives gave rise to income of EUR 30,002k (comparative period: EUR 23,394k) and expenses of EUR 43,452k (comparative period: EUR 34,314k).

Other assets and other liabilities

EUR k	31 Jan 2012	31 Jul 2012
Prepayments	37,492	40,402
Tax claims – VAT and other taxes	9,574	21,633
Sundry assets	33,784	44,005
Other assets	**80,850**	**106,040**

EUR k	31 Jan 2012	31 Jul 2012
VAT and other tax liabilities	93,827	68,731
Personnel liabilities	106,670	106,275
Liabilities relating to social security/similar charges	17,499	17,836
Prepayments received on account	9,805	9,526
Sundry liabilities	50,313	55,738
Other liabilities	**278,114**	**258,106**

Other financial assets and other financial liabilities

The table below presents the non-current financial assets:

EUR k	31 Jan 2012	31 Jul 2012
Available-for-sale financial assets	42,402	42,165
Loans to and receivables from associates	8,490	7,791
Other loans	12,516	11,609
Other non-current financial assets	842	854
	64,250	**62,419**

The table below presents the current financial assets:

EUR k	31 Jan 2012	31 Jul 2012
Trade receivables	2,533,903	2,402,754
Other financial assets		
Held-to-maturity financial assets	59	58
Available-for-sale financial assets	35	0
Loans to and receivables from associates or related parties	3,191	2,976
Other loans	38,675	41,484
Derivative financial instruments	1,006	1,132
Other current financial assets	105,928	126,415
	148,894	**172,065**

The receivables from factoring and ABS transactions as of 31 July 2012 are presented below:

EUR k	31 Jan 2012	31 Jul 2012
Receivables not derecognised in accordance with IAS 39		
Volume of receivables	244,766	244,500
Financial liability	247,854	199,183
Receivables derecognised in accordance with IAS 39		
Volume of receivables	74,760	79,856
Continuing involvement		
Volume of receivables	265,331	300,589
Continuing involvement	17,430	22,784
Financial liability	18,370	23,880
Retentions	36,305	53,426

At the reporting date financial liabilities were split between non-current and current liabilities as follows:

EUR k	31 Jan 2012	31 Jul 2012
Financial liabilities (non-current)		
Liabilities to banks	651,758	298,656
Bonds	482,369	485,065
Loans	575	551
Supplementary partner contribution	123,766	123,766
Other financial liabilities	26,685	27,304
	1,285,153	**935,342**

EUR k	31 Jan 2012	31 Jul 2012
Financial liabilities (current)		
Liabilities to banks	260,850	572,922
Loans	110,518	108,856
Liabilities to associates and related parties	45,619	40,859
Liabilities and provisions for customer rebates and bonuses	21,209	22,667
ABS and factoring liabilities and payables	266,224	223,063
Other financial liabilities	46,803	44,226
	751,223	**1,012,593**

Under the refinancing taken place in June 2012, the PHOENIX group signed a EUR 1.35bn syndicated facilities agreement. The long-term tranche of the facility agreement with a nominal amount of EUR 300,000k and a term of four years is presented within non-current liabilities to banks. Moreover, the PHOENIX group has access to a EUR 1,050,000k revolving credit facility with a term of five years.

In connection with the loan agreements, it was agreed to comply with certain financial covenants, all of which were comfortably met in the first half year of 2012/13.

Other financial liabilities (non-current) contain non-current derivative financial instruments of EUR 1,567k (31 January 2012: EUR 849k).

Liabilities to associates and related parties include current loan liabilities to partners of EUR 40,327k (31 January 2012: EUR 45,185k), resulting mainly from interest on the supplementary partner contribution.

Other financial liabilities (current) contain current derivative financial instruments of EUR 6,933k (31 January 2012: EUR 7,434k).

Commitments and contingent liabilities

Compared to 31 January 2012, commitments increased by EUR 10,752k to EUR 504,183k. This mainly reflects the changes in volumes of goods ordered.

PHOENIX recorded contingent liabilities for warranties of EUR 123,844k (31 January 2012: EUR 121,807k).

Notes to the statement of cash flows

EUR k	31 Jan 2012	31 Jul 2012
Restricted cash		
Cash and cash equivalents at the end of the period	334,846	109,772
Thereof restricted:		
Due to security deposits	5,109	9,035
Due to restrictions placed upon foreign subsidiaries	11,185	8,823

Related party disclosures

The business relationships with related parties presented in the consolidated financial statements as of 31 January 2012 remained essentially unchanged in the first quarter of 2012/13.

Mannheim, 13 September 2012

Management of the unlimited partner
PHOENIX Verwaltungs GmbH

Financial calendar 2012/2013

27th June 2012	**Quarterly Report February to April 2012**
27th September 2012	**Quarterly Report February to July 2012**
20th December 2012	**Quarterly Report February to October 2012**

Imprint

Translation of the German version.
The German version is binding.

Contact

Group Communications PHOENIX group
Pfingstweidstraße 10 - 12
68199 Mannheim
Germany
Phone +49 (0)621 8505 8502
Fax +49 (0)621 8505 8501
media@PHOENIXgroup.eu
www.PHOENIXgroup.eu

The text of the annual report applies equally to both women and men. Any exclusive use of the female or male form encompasses both forms.

PHOENIX group

We deliver health.

PHOENIX Pharmahandel
GmbH & Co KG
Pfingstweidstraße 10-12
68199 Mannheim
Germany
www.PHOENIXgroup.eu